Press releases

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD has reached an agreement with the U.S. Securities and Exchange...

Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J., Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective...

Company Reinforces its Longstanding Commitment to Help Improve Health Equity and Expand Access to Care Among Vulnerable Populations FRANKLIN LAKES, N.J., Dec. 11, 2023 /PRNewswire/ -- BD (Becton,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety...

WASHINGTON, D.C., USA, Nov. 20, 2023 – BD (Becton Dickinson and Company), a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a...

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which...

Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery of more than 320 million doses through 2030 Previously guaranteed...

Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion...

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA)...

BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and...

Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J., Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson...

Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base...

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4...

Diagnostic Research Center Enables Students to Test and Develop Clinical Workflows to Help Shape Laboratory Performance and Patient Outcomes FRANKLIN LAKES, N.J., Sept. 27, 2022 /PRNewswire/ -- BD...

Research Use Only (RUO) assay now globally available for BD MAX™ System FRANKLIN LAKES, N.J., Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

BD EffivaxTM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs...

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as...

Acquisition adds to company's recent growth in high-technology pharmacy solutions and further accelerates the company's commitment to Smart, Connected Care – offering a customizable platform to...

Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive FRANKLIN LAKES, N.J., June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today unveiled findings from a survey conducted by The Harris...

Second Test for the BD COR™ MX to be CE Marked to IVD Directive FRANKLIN LAKES, N.J., May 26, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)...

Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline...

FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that in the interest of the health and safety of its shareholders, directors, officers,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now available for purchase through Everly Health, a...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Embecta Corp. ("embecta"), the independent, publicly-traded company that will hold...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that "embecta" [pronounced em-BECK-tah] will be the name of the independent,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern....

FRANKLIN LAKES, N.J. (November 16, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, broke ground on a €165 million ($200 million USD)...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will begin its Investor Day at 8 a.m. ET today to share how it plans to leverage the breadth and depth...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021....

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has started to ship the first over-the-counter (OTC) COVID-19 rapid antigen test to...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been selected by the state of Washington as a digitally read, rapid antigen test...

CANAAN, Conn. (Sept. 2, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 60th anniversary of its manufacturing facility...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...

FRANKLIN LAKES, N.J. (Aug. 10, 2021) — BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health...

ZARAGOZA, SPAIN and FRANKLIN LAKES, N.J. (Aug. 6, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec, today announced the CE...

Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD's COVID-19 testing revenues were $300 million, including BD...